S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 38

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Oct 14, 2014; 20(38): 13987-13992
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13987

Table 1 Characteristics of the patients n (%)

Characteristic	Number of patients
Age (yr)
Range	50-69
Median	55
Gender
Female	17 (53.12)
Male	15 (46.88)
Karnofsky performance status
100	20 (62.5)

Citation: Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer. World J Gastroenterol 2014; 20(38): 13987-13992
URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13987.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13987

Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer. World J Gastroenterol 2014; 20(38): 13987-13992 [PMID: 25320537 DOI: 10.3748/wjg.v20.i38.13987]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.